Clinical Trial Update: A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults [Phase 2]

View source ↗

Summary

Phase 2 study evaluating BYM338 for skeletal muscle effects in adults with sarcopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcopenia

Drugs mentioned

• BYM338

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Skeletal Muscle | Phase 2 | Status: COMPLETED